placeholder
Importance
55
Trust
80
Urgency
30
REGULATORY · PRIMARY SOURCE
NativeMed LLC dba NativeMed - 728287 - 06/08/2026
The FDA warned NativeMed, a Miami-based compounding pharmacy, for making false claims about its weight-loss drugs semaglutide and tirzepatide. The agency said NativeMed's website falsely suggested the compounded versions were FDA-approved and implied NativeMed made the drugs when it did not.
Analysis
FDA is actively warning compounders who misrepresent their semaglutide and tirzepatide products. This pushes patients toward Novo's and Lilly's brand-name drugs.
- FDA reviewed NativeMed's website in March 2026 and issued warning letter on June 8, 2026
- NativeMed's logo appeared on tirzepatide product labels, falsely implying it was the compounder
- Website claimed compounded semaglutide contained 'The same active ingredient in Ozempic® and Wegovy®'
FDA Drug Approvals & Databases4d
Read